+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Opioids Market Size, Share & Trends Analysis Report By Product (IR/ Short-acting, ER/Long-acting), By Application (Pain Relief, Anesthesia), By Region, And Segment Forecasts, 2019 - 2026

  • ID: 4538721
  • Report
  • 113 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • ALLERGAN (Actavis)
  • Grunenthal GmbH
  • Pfizer, Inc.
  • Purdue Pharma L.P
  • Sanofi-Aventis S.A.
  • MORE
The global opioids market size is estimated to reach USD 29.4 billion by 2026, expanding at a CAGR of 1.8% over the forecast period. Growing geriatric population, coupled with increasing focus on palliative care, is estimated to drive the market. Moreover, increasing geographical expansions by market players is expected to fuel growth.

Rising prevalence of disease conditions with chronic pain, such as cancer, lower back pain, arthritis, and fibromyalgia, is driving the opioids market. Substantial rise in road accidents and trauma, coupled with constantly increasing cases of surgical procedures, is also driving demand for opioid-based pain management solutions.

On the basis of product, ER was the dominant segment in 2018 owing to its high usage in chronic pain management. However, the abuse and misuse of these drugs have resulted in a serious public health crisis.

North America led the market in 2018 with a share of 55.5% in terms of revenue. One of the major reasons for its dominance is rising geriatric population with terminal conditions, such as rheumatoid arthritis. However, opioid abuse in U.S. has been rising at an alarming rate. Overdose has killed over 28,000 people in 2014 alone. Almost half of those deaths were caused by prescription drugs. Hence, drug abuse has been declared a “public health emergency” in U.S. and this is likely to limit market growth in North America.

According to the federal government, around 4,000 Canadians died due to opioid-related overdose in 2017, which is a 34% jump from the previous year. Globally, Canadians are one of the highest users of prescription opioids and this rate, along with associated deaths and hospital visits, has been growing rapidly. To combat this, Health Canada aims to restrict the marketing of such drugs.

The federal government is calling on pharmaceutical companies to stop marketing opioids. For instance, Purdue Pharma has stopped marketing its opioids in Canada, thereby limiting the growth of the North America market. The company has, in fact, shifted its focus to other regions, such as Asia Pacific, to retain its hold in the market. APAC is likely to witness the fastest growth in the coming years.

Further key findings from the study suggest:
  • Extended release was the largest product segment in 2018 due to its high usage in chronic pain management
  • Cancer pain was the largest pain relief segment in 2018 owing to global increase in prevalence of cancer
  • North America was the largest regional market in 2018, driven by presence of key players and highest use of prescription opioids
  • Europe was the second-largest regional market in 2018, primarily fuelled by growing geriatric population
  • Asia Pacific is expected to witness the fastest growth over the forecast period due to increase in geriatric population, coupled with shifting focus of key players towards this region in order to strengthen their position
  • Some of the key players are Purdue Pharma L.P; West-Ward Pharmaceuticals Corporation; Allergan; Pfizer, Inc.; Janssen Pharmaceuticals, Inc.; Egalet Corporation; and Sun Pharmaceutical Industries Limited. Most key players are focusing on entering untapped regions and expanding their product portfolios.

Please Note: This report will be delivered within 3 business days of ordering
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ALLERGAN (Actavis)
  • Grunenthal GmbH
  • Pfizer, Inc.
  • Purdue Pharma L.P
  • Sanofi-Aventis S.A.
  • MORE
Chapter 1 Methodology and Scope
1.1.Market Segmentation & scope
1.2. Market Definition
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources & third party perspectives
1.3.4. Primary research
1.4. Information Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Data Visualization
1.6. Data Validation & Publishing

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Global Opioids Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Regulatory Framework
3.2.1. Reimbursement framework
3.2.2. Standards & compliances
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Expanding application of opioids in various therapeutic conditions
3.3.1.2. Expanding target audience for the opioid market
3.3.2. Market restraint analysis
3.3.2.1. Stringent regulatory framework
3.3.2.2 Opioid abuse and dependency
3.4. Global Opioids Market Analysis Tools
3.4.1. Industry analysis - Porter’s
3.4.1.1. Supplier power: (Low due to government control on pricing)
3.4.1.2. Buyer power: (High due to availability of wide-range of generic products)
3.4.1.3. Substitution threat: (High due to highly regulated supply of opioids)
3.4.1.4. Threat from new entrant: (Low due to strict regulations and guidelines)
3.4.1.5. Competitive rivalry: (Moderate due to presence of few key players)
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Environmental landscape
3.4.2.3. Social landscape
3.4.2.4. Technology landscape
3.4.2.5. Legal landscape
3.4.3. Major deals & strategic alliances analysis
3.4.3.1. Joint ventures
3.4.3.2. Mergers & acquisitions
3.4.3.3. Licensing & partnership
3.4.3.4. Technology collaborations
3.4.3.5. Strategic divestments

Chapter 4. Global Opioids Market - Competitive Analysis
4.1. Recent Developments & Impact Analysis, by Key Market Participants
4.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
4.3. Vendor Landscape
4.3.1. List of key distributors and channel partners
4.3.2. Key company market share analysis, 2018
4.4. Public Companies
4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
4.4.2. Company market share
4.4.3. Competitive dashboard analysis
4.4.4. Market differentiators
4.4.5. Synergy analysis: Major deals & strategic alliances
4.5. Private Companies
4.5.1. List of key emerging companies
4.5.2. Regional network map
4.5.3. Company market position analysis (Geographic presence, product portfolio, key alliance, industry experience)

Chapter 5. Global Opioids Market: Product Estimates & Trend Analysis
5.1. Definitions & Scope
5.2. Product Market Share Analysis, 2018 & 2026
5.3. Global Opioids Market, by Product, 2014 to 2026
5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the Following,
5.4.1. Immediate-release/Short-acting opioid
5.4.1.1 Immediate-release/Short-acting opioid market, 2014 - 2026 (USD Billion)
5.4.1.2 Codeine
5.4.1.2.1 Codeine market, 2014 - 2026 (USD Billion)
5.4.1.3 Oxycodone
5.4.1.3.1 Oxycodone market, 2014 - 2026 (USD Billion)
5.4.1.4 Hydrocodone
5.4.1.4.1 Hydrocodone market, 2014 - 2026 (USD Billion)
5.4.1.5 Fentanyl
5.4.1.5.1 Fentanyl market, 2014 - 2026 (USD Billion)
5.4.1.6 Morphine
5.4.1.6.1 Morphine market, 2014 - 2026 (USD Billion)
5.4.1.7 Hydroxymorphone
5.4.1.7.1 Hydroxymorphone market, 2014 - 2026 (USD Billion)
5.4.1.8 Oxymorphone
5.4.1.8.1 Oxymorphone market, 2014 - 2026 (USD Billion)
5.4.1.9 Propoxyphene
5.4.1.9.1 Propoxyphene market, 2014 - 2026 (USD Billion)
5.4.1.10 Others
5.4.1.10.1 Others market, 2014 - 2026 (USD Billion)
5.4.2. Extended-release/Long-acting opioid
5.4.2.1 Extended-release/Long-acting opioid market, 2014 - 2026 (USD Billion)
5.4.2.2 Oxycodone
5.4.2.2.1 Oxycodone market, 2014 - 2026 (USD Billion)
5.4.2.3 Hydrocodone
5.4.2.3.1 Hydrocodone market, 2014 - 2026 (USD Billion)
5.4.2.4 Methadone
5.4.2.4.1 Methadone market, 2014 - 2026 (USD Billion)
5.4.2.5 Fentanyl
5.4.2.5.1 Fentanyl market, 2014 - 2026 (USD Billion)
5.4.2.6 Morphine
5.4.2.6.1 Morphine market, 2014 - 2026 (USD Billion)
5.4.2.7 Oxymorphone
5.4.2.7.1 Oxymorphone market, 2014 - 2026 (USD Billion)
5.4.2.8 Tapentadol
5.4.2.8.1 Tapentadol market, 2014 - 2026 (USD Billion)
5.4.2.9 Buprenorphine
5.4.2.9.1 Buprenorphine market, 2014 - 2026 (USD Billion)
5.4.2.10 Hydromorphone
5.4.2.10.1 Hydromorphone market, 2014 - 2026 (USD Billion)
5.4.2.11 Others
5.4.2.11.1 Others market, 2014 - 2026 (USD Billion)
5.5. Product Markets, by Application, 2014 to 2026:
5.5.1. Immediate-release/Short-acting opioid
5.5.1.1 Pain relief
5.5.1.1.1 Pain relief market, 2014 - 2026 (USD Billion)
5.5.1.2 Anesthesia
5.5.1.2.1 Anesthesia market, 2014 - 2026 (USD Billion)
5.5.1.3 Cough suppression
5.5.1.3.1 Cough suppression market, 2014 - 2026 (USD Billion)
5.5.1.4 Diarrhea
5.5.1.4.1 Diarrhea market, 2014 - 2026 (USD Billion)
5.5.1.5 De-addiction
5.5.1.5.1 De-addiction market, 2014 - 2026 (USD Billion)
5.5.2. Extended-release/Long-acting opioid
5.5.2.1 Pain relief
5.5.2.1.1 Pain relief market, 2014 - 2026 (USD Billion)
5.5.2.2 Anesthesia
5.5.2.2.1 Anesthesia market, 2014 - 2026 (USD Billion)
5.5.2.3 Cough suppression
5.5.2.3.1 Cough suppression market, 2014 - 2026 (USD Billion)
5.5.2.4 Diarrhea
5.5.2.4.1 Diarrhea market, 2014 - 2026 (USD Billion)
5.5.2.5 De-addiction
5.5.2.5.1 De-addiction market, 2014 - 2026 (USD Billion)

Chapter 6. Global Opioids Market: Application Estimates & Trend Analysis
6.1. Definitions & Scope
6.2. Application Market Share Analysis, 2018 & 2026
6.3. Global Opioids Market, by Application, 2014 to 2026
6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the Following,
6.4.1. Pain relief
6.4.1.1 Pain relief market, 2014 - 2026 (USD Billion)
6.4.1.2 Cancer pain
6.4.1.2.1 Cancer pain market, 2014 - 2026 (USD Billion)
6.4.1.3 Postoperative pain
6.4.1.3.1 Postoperative pain market, 2014 - 2026 (USD Billion)
6.4.1.4 Low back pain
6.4.1.4.1 Low back pain market, 2014 - 2026 (USD Billion)
6.4.1.5 Orthopedic
6.4.1.5.1 Orthopedic market, 2014 - 2026 (USD Billion)
6.4.1.6 Neuropathic pain
6.4.1.6.1 Neuropathic pain market, 2014 - 2026 (USD Billion)
6.4.1.7 Fibromyalgia
6.4.1.7.1 Fibromyalgia market, 2014 - 2026 (USD Billion)
6.4.2. Anesthesia
6.4.2.1 Anesthesia market, 2014 - 2026 (USD Billion)
6.4.3. Cough suppression
6.4.3.1 Cough suppression market, 2014 - 2026 (USD Billion)
6.4.4. Diarrhea suppression
6.4.4.1 Diarrhea suppression market, 2014 - 2026 (USD Billion)
6.4.5. De-addiction
6.4.5.1 De-addiction market, 2014 - 2026 (USD Billion)

Chapter 7 Global Opioids Market: Regional Estimates & Trend Analysis, by Product, Technology, Application, & End-use
7.1 Global Opioids Market: Regional Movement Analysis, 2018 & 2026
7.2 Global Opioids Market: Leading Players, 2018:
7.2.1. North America
7.2.2. Europe
7.2.3. Asia Pacific
7.2.4. Latin America
7.2.5. Middle East & Africa
7.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa
7.4 North America
7.4.1 North America opioids market, 2014 - 2026 (USD Billion)
7.4.2 U.S.
7.4.2.1 U.S. opioids market, 2014 - 2026 (USD Billion)
7.4.3 Canada
7.4.3.1 Canada opioids narket, 2014 - 2026 (USD Billion)
7.5. Europe
7.5.1 Europe opioids market, 2014 - 2026 (USD Billion)
7.5.2 U.K.
7.5.2.1 U.K. opioids market, 2014 - 2026 (USD Billion)
7.5.3 Germany
7.5.3.1 Germany opioids market, 2014 - 2026 (USD Billion)
7.5.4 France
7.5.4.1 France opioids market, 2014 - 2026 (USD Billion)
7.5.5 Spain
7.5.5.1 Spain opioids market, 2014 - 2026 (USD Billion)
7.5.6 Italy
7.5.6.1 Italy opioids market, 2014 - 2026 (USD Billion)
7.6 Asia Pacific
7.6.1 Asia Pacific opioids market, 2014 - 2026 (USD Billion)
7.6.2 Japan
7.6.2.1 Japan opioids market, 2014 - 2026 (USD Billion)
7.6.3 China
7.6.3.1 China opioids market, 2014 - 2026 (USD Billion)
7.6.4 India
7.6.4.1 India opioids market, 2014 - 2026 (USD Billion)
7.6.5 South Korea
7.6.5.1 South Korea opioids market, 2014 - 2026 (USD Billion)
7.6.6 Singapore
7.6.6.1 Singapore opioids market, 2014 - 2026 (USD Billion)
7.6.7 Australia
7.6.7.1 Australia opioids market, 2014 - 2026 (USD Billion)
7.7 Latin America
7.7.1 Latin America opioids market, 2014 - 2026 (USD Billion)
7.7.2 Brazil
7.7.2.1 Brazil opioids market, 2014 - 2026 (USD Billion)
7.7.3 Mexico
7.7.3.1 Mexico opioids market, 2014 - 2026 (USD Billion)
7.7.4 Argentina
7.7.4.1 Argentina opioids market, 2014 - 2026 (USD Billion)
7.8 MEA
7.8.1 MEA opioids market, 2014 - 2026 (USD Billion)
7.8.2 South Africa
7.8.2.1 South Africa opioids market, 2014 - 2026 (USD Billion)
7.8.3 United Arab Emirates
7.8.3.1 United Arab Emirates opioids market, 2014 - 2026 (USD Billion)
7.8.4 Saudi Arabia
7.8.4.1 Saudi Arabia opioids market, 2014 - 2026 (USD Billion)

Chapter 8 Competitive Landscape
8.1 Strategy Framework
8.2 Heat Map Analysis of Private Companies
8.2.1 Company size
8.2.2 Distribution network
8.2.3 Product portfolio
8.2.4 Segment coverage
8.2.5 Geographic presence
8.2.6 Collaborations
8.2.7 Conclusion
8.3 Purdue Pharma L.P
8.3.1 Company overview
8.3.2 Financial performance
8.3.3 Product benchmarking
8.3.4 Strategic initiatives
8.4 Janssen Pharmaceuticals, Inc.
8.4.1 Company overview
8.4.2 Financial performance
8.4.3 Product benchmarking
8.4.4 Strategic initiatives
8.5 West-Ward Pharmaceuticals Corporation
8.5.1 Company overview
8.5.2 Financial performance
8.5.3 Product benchmarking
8.5.4 Strategic initiatives
8.6 Pfizer, Inc.
8.6.1 Company overview
8.6.2 Financial performance
8.6.3 Product benchmarking
8.6.4 Strategic initiatives
8.7 ALLERGAN (Actavis)
8.7.1 Company overview
8.7.2 Financial performance
8.7.3 Product benchmarking
8.7.4 Strategic initiatives
8.8 Sanofi-Aventis S.A.
8.8.1 Company overview
8.8.2 Financial performance
8.8.3 Product benchmarking
8.8.4 Strategic initiatives
8.9 Sun Pharmaceutical Industries Limited
8.9.1 Company overview
8.9.2 Financial performance
8.9.3 Product benchmarking
8.9.4 Strategic initiatives
8.10 Grunenthal GmbH
8.10.1 Company overview
8.10.2 Financial performance
8.10.3 Product benchmarking
8.10.4 Strategic initiatives

*Full List of Tables and Figures Available on Enquiry.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Purdue Pharma L.P
  • Janssen Pharmaceuticals, Inc.
  • West-Ward Pharmaceuticals Corporation
  • Pfizer, Inc.
  • ALLERGAN (Actavis)
  • Sanofi-Aventis S.A.
  • Sun Pharmaceutical Industries Limited
  • Grunenthal GmbH
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4538721
Adroll
adroll